<DOC>
	<DOCNO>NCT00724464</DOCNO>
	<brief_summary>The objective study evaluate rate Hepatitis C virus ( HCV ) eradication relapse participant treat PegIntron Rebetol clinical practice Greece . Participants treat part study . Data participant treat accordance approve label collect retrospectively approximately 30 site Greece .</brief_summary>
	<brief_title>Efficacy PegIntron ( Peginterferon Alfa-2b ) Rebetol ( Ribavirin ) Treatment-na√Øve Subjects With Chronic Hepatitis C Clinical Practice Greece ( Study P05209 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Participants already begin Summary Product Characteristics ( SmPC ) base combination treatment pegylated interferon alpha2b ribavirin , prior site initiation date . Participants receive combination treatment pegylated interferon alpha2b ribavirin least 6 month enrollment . Participants achieve negative HCV RNA end treatment , define accord genotype ( 24 week HCV genotypes 2/3 48 week genotypes 1/4 ) . Participants diagnose chronic hepatitis C ( CHC ) HCV genotype 1 , 2 , 3 4 . Participants older 18 year , regardless gender race . The participant receive treatment CHC past ( treatmentnaive ) . The participant receive treatment context clinical trial participate site . The participant diagnose concomitant infection e.g . hepatitis B HIV The participant decompensated liver disease belong special population , liver transplant , hemophilia , severe preexist psychiatric disorder , autoimmune disease , thalassaemia . The participant positive HCV RNA end treatment . Pregnant woman woman intend bear child sexual partner woman wish bear child 7month period end treatment , indicate SmPC Rebetol . The participant eligible ground contraindication , special warning , particular population and/or section pregnancy lactation SmPC . The participant interrupt treatment reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>